CSPC RECOMGEN PHARMACEUTICAL (GUANGZHOU) CO., LTD.
石藥集團明復(fù)樂藥業(yè)(廣州)有限公司
CSPC RECOMGEN PHARMACEUTICAL (GUANGZHOU) CO., LTD. (formerly known as "Guangzhou Recomgen Biotech Co., Ltd.") was founded in Guangzhou in 2000, is an innovative biopharmaceutical company focusing on the large-scale serum-free continuous animal cell culture technology and the R&D of new biologicl drugs. In 2022, it was merged into CSPC Pharmaceutical Group Limited (stock code: 1093). In the future, the company will follow the strategic planning of the Group and continue to enrich macromolecule product pipelines, to become an important basis of CSPC in the Greater Bay Area of China.
rhTNK-tPA, the latest generation specific thrombolytic drug dependently developed by the company, was approved in 2015, filling the gap in this field in China. As the Significant New drugs Creation Project during 12th Five-Year plan and the only third-generation rhTNK t-PA product in China, rhTNK-tPA is the only drug that can be injected intravenously in a single dose, which is conventient and suitable for emergency treatment and out-of-hospital thrombolysis as needed. It will enhance the treatment rate, improve the clinical benefit as well as reduce the personal and societal medical burdens in terms of patients with acute myocardial infarction received thrombolytic therapy.
The Phase III clinical trial of rhTNK-tPA for the treatment of acute ischemic stroke (AIS) has completed the enrollment of patients. This research is aimed to improve the accessibility of the drug and save more lives of stroke patients, and reduce the disability rate. We look forward to fill the gap of the third-generation thrombolytic drugs in treating ischemic stroke worldwide.
With the mission of Social responsibility on shoulders, Human health in heart, we will continuously focus on technological innovation and drug quality, aiming to build the world's top brand of thrombolytic therapy and becoming a leading biopharmaceutical company globally.
